FibroGen (FGEN) Tops Q4 EPS by 35c

FibroGen (NASDAQ: FGEN) reported Q4 EPS of $0.18, $0.35 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $22.09 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Evercore ISI Upgrades The Macerich Company (MAC) to Outperform, 'improving balance sheet and accelerating FFO growth'
• JPMorgan Reiterates Overweight Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
• Fluence Energy Inc. (FLNC) PT Lowered to $6 at Mizuho